WO2005120589A3 - Contrast agent comprising alginate and an isotope or paramagnetic ion - Google Patents

Contrast agent comprising alginate and an isotope or paramagnetic ion Download PDF

Info

Publication number
WO2005120589A3
WO2005120589A3 PCT/NO2005/000205 NO2005000205W WO2005120589A3 WO 2005120589 A3 WO2005120589 A3 WO 2005120589A3 NO 2005000205 W NO2005000205 W NO 2005000205W WO 2005120589 A3 WO2005120589 A3 WO 2005120589A3
Authority
WO
WIPO (PCT)
Prior art keywords
manganese
alginate
ions
compound
isotope
Prior art date
Application number
PCT/NO2005/000205
Other languages
French (fr)
Other versions
WO2005120589A2 (en
Inventor
Christian Brekken
Yrr Moerch
Original Assignee
Ntnu Technology Transfer
Christian Brekken
Yrr Moerch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ntnu Technology Transfer, Christian Brekken, Yrr Moerch filed Critical Ntnu Technology Transfer
Publication of WO2005120589A2 publication Critical patent/WO2005120589A2/en
Publication of WO2005120589A3 publication Critical patent/WO2005120589A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature

Abstract

A system for the delivery of contrast agents such as manganese (MR-active Mn2+ or other manganese isotopes) into extravascular body compartments in living subjects (mammals, amphibians, fish etc.) is described. The compound consists of alginate, manganese ions and other stabilizing ions (Ba2+, Ca2+ etc.) in a gel, formed by mixing of alginate and solutions of the ions mentioned above. The primary alginate used in production of the compound can be adjusted in structure (M- and G-block content and sequence), molecular weight and concentration. In addition, the salt solution and concentration can be varied in order to produce alginate gels of variable manganese amount (dose) and local manganese release rate (dose-rate). When injected or implanted into extravascular body compartments manganese ions will be released from the gel by ion exchange with body fluids and passive diffusion. Once released the manganese ions shortens the longitudinal MR relaxation time of water molecules in their vicinity amounting to positive image contrast in T1-weighted MR images. Furthermore, the compound may also act as slow release agent for positron emission tomography scanning, provided the manganese-isotope is emitting positrons (m52mMn).
PCT/NO2005/000205 2004-06-14 2005-06-13 Contrast agent comprising alginate and an isotope or paramagnetic ion WO2005120589A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20042486 2004-06-14
NO20042486A NO320691B1 (en) 2004-06-14 2004-06-14 New contrast release system.

Publications (2)

Publication Number Publication Date
WO2005120589A2 WO2005120589A2 (en) 2005-12-22
WO2005120589A3 true WO2005120589A3 (en) 2006-06-15

Family

ID=35005930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2005/000205 WO2005120589A2 (en) 2004-06-14 2005-06-13 Contrast agent comprising alginate and an isotope or paramagnetic ion

Country Status (2)

Country Link
NO (1) NO320691B1 (en)
WO (1) WO2005120589A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156189B2 (en) * 2010-10-01 2015-10-13 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003781A1 (en) * 1984-12-17 1986-07-03 Sintef Process for producing alginates having improved physical properties, and the use of said alginates
WO1993010440A1 (en) * 1991-11-19 1993-05-27 Unger Evan C Gel particle contrast media for improved diagnostic imaging
WO2003045457A2 (en) * 2001-11-27 2003-06-05 Scimed Life Systems, Inc. Medical devices visible under magnetic resonance imaging
WO2003086474A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003781A1 (en) * 1984-12-17 1986-07-03 Sintef Process for producing alginates having improved physical properties, and the use of said alginates
WO1993010440A1 (en) * 1991-11-19 1993-05-27 Unger Evan C Gel particle contrast media for improved diagnostic imaging
WO2003045457A2 (en) * 2001-11-27 2003-06-05 Scimed Life Systems, Inc. Medical devices visible under magnetic resonance imaging
WO2003086474A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EMMERICHS N.: "Interaction between alginates and manganese cations: identification of preferred cation binding sites", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 34, 2004, pages 73 - 79, XP008060943 *
GOTOH T. ET AL: "Adsorption of Cu and Mn on covalently cross-linked alginate beads", CHEMOSPHERE, vol. 55, 2004, pages 57 - 64, XP008060940 *
KLÖCH G. ET AL: "Production of purified alginates suitable for use in immunoisolated trasplantation", APPL MICROBIOL BIOTECHNOL, vol. 40, 1994, XP008061137 *
NOETH U ET AL: "19F-MRI IN VIVO DETERMINATION OF THE PARTIAL OXYGEN PRESSURE IN PERFLUOROCARBON-LOADED ALGINATE CAPSULES IMPLANTED INTO THE PERITONEAL CAVITY AND DIFFERENT TISSUES", MAGNETIC RESONANCE IN MEDICINE, ACADEMIC PRESS, DULUTH, MN, US, vol. 42, no. 6, 1999, pages 1039 - 1047, XP001162703, ISSN: 0740-3194 *
ZIMMERMANN H ET AL: "Fabrication of homogeneously cross-linked, functional alginate microcapsules validated by NMR-, CLSM- and AFM-imaging", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 24, no. 12, May 2003 (2003-05-01), pages 2083 - 2096, XP004413509, ISSN: 0142-9612 *

Also Published As

Publication number Publication date
NO20042486L (en) 2005-12-15
NO320691B1 (en) 2006-01-16
WO2005120589A2 (en) 2005-12-22
NO20042486D0 (en) 2004-06-14

Similar Documents

Publication Publication Date Title
Zhang et al. Biological utility of fluorinated compounds: from materials design to molecular imaging, therapeutics and environmental remediation
Jalloh et al. Glucose metabolism following human traumatic brain injury: methods of assessment and pathophysiological findings
Matsuki et al. Oxygen supersaturated fluid using fine micro/nanobubbles
Sohn et al. Anticonvulsant drug mechanisms: phenytoin, phenobarbital, and ethosuximide and calcium flux in isolated presynaptic endings
CN1093893A (en) Altered dipole moment magnetic resonance imaging method
RU2010128067A (en) POLYMERIC MEDICINAL CARRIER FOR DELIVERY UNDER VISUAL CONTROL
McCoy et al. The effect of blood flow modification on intra-and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours
Hyppönen et al. Metabolism of hyperpolarised [1–13C] pyruvate in awake and anaesthetised rat brains
US9198988B2 (en) Nanoparticulate manganese MRI contrast agents
WO2005120589A3 (en) Contrast agent comprising alginate and an isotope or paramagnetic ion
Olson et al. Ultrasound detection of regional oxidative stress in deep tissues using novel enzyme loaded nanoparticles
BRPI0510950A (en) specific binding member, pharmaceutical composition, method for treating a tumor in a patient, use of a binding member, products, nucleic acid, and sialyl tetraosyl carbohydrate
Henriques A technique of studying salivary gland function
Joo et al. L‐glutamine as a T2 exchange contrast agent
CN103040756B (en) A kind of preparation method of mPEG epirubicin hydrochloride magnetic liposome
RU2015152544A (en) METHODS FOR USING RIFAXIMINE FOR SCANNING BY POSITRON EMISSION TOMOGRAPHY (PET)
Suzuki et al. Effect of intravenous infusion of isotonic sodium bicarbonate solution on acidemic calves with diarrhea
Shih et al. Preparation and therapeutic evaluation of 188Re-thermogelling emulsion in rat model of hepatocellular carcinoma
CN101204371B (en) Vitamin C injection and preparation method thereof
Beech et al. Bicarbonate in the treatment of metabolic acidosis: effects on hepatic intracellular pH, gluconeogenesis, and lactate disposal in rats
CN110585448B (en) Nano diagnosis and treatment agent for acute kidney injury and preparation method and application thereof
Lu et al. Fabrication of Mn2+-Doped Hollow Mesoporous Aluminosilica Nanoparticles for Magnetic Resonance Imaging and Drug Delivery for Therapy of Colorectal Cancer
Bokacheva et al. Response of HT29 colorectal xenograft model to cediranib assessed with 18F‐fluoromisonidazole positron emission tomography, dynamic contrast‐enhanced and diffusion‐weighted MRI
EP1519757B1 (en) Scanning suspension comprising a particle with a diameter of at least 1 micrometer
Ceberg et al. Modelling the dynamic dose response of an nMAG polymer gel dosimeter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase